Industry Insights

To further increase your knowledge of the cold chain industry, we provide you with the latest trends, facts, and innovations.

Subscribe to our Newsletter so you won't miss out on any essential information.

Subscribe Now

How pharma can save money and be friendlier to the planet

In the pharma industry, approximately 90% of all carbon emissions are generated in the manufacturing phase. The biggest positive impact on carbon emissions the secure cold chain can have is therefore to ensure that every single dose that is manufactured reaches the patient securely and on time.

Why pharma should spend an hour or two on Total Landed Cost

When shipping vaccines or any other temperature-sensitive medical solution, pharmaceutical companies look for partners that ensure high quality, that can simplify the handling process, and help to reduce CO2 emissions. While active temperature-controlled solutions meet all those requirements, the general perception is that they are more expensive. That perception sometimes makes pharmaceutical companies choose other, seemingly less costly alternatives, commonly known as passive solutions, not realizing that they are in essence, paying more for an inferior solution.

Different alternatives for temperature-controlled transport

Breakthrough research in various medical fields, such as gene editing, stem cell technology and regenerative medicine, has led to an increased demand for temperature-controlled transport. High-end, specialized medicine is often produced in low volumes with no backup stock and thus, delivering these sensitive products safely across the globe has become a mounting logistical challenge. Selecting a secure and reliable logistics solution has accordingly become all the more important.

Defining the best procurement process strategy for pharma logistics

To make it simple, procurement is about getting the right products and the right services at the right price. With complex products and services, however, the procurement process is more than just buying upfront. Integrated, multifaceted systems and services need a strategic approach that is focused on efficiency rather than costs. Temperature-controlled pharmaceutical transport – with its many stakeholders, highly regulated environment and precious products – is precisely such an area that pinpoints the strategic importance of the procurement function. And with the recent development on the market, to procure logistics is not getting any easier.

The keys to succeed with pharma cold chain transportation from Mexico

Mexico has potential for becoming a large exporter of pharmaceuticals, while having an attractive home market for pharmaceutical sales as well. For those who want to take advantage of the rising opportunities in Mexico, there are specific challenges that must be taken into account regarding cold chain transportation of high-quality pharmaceuticals.

Good Reads #6: The changing role of the pharma procurement function

Pharma cold chain logistics is very complex with many stakeholders involved. We all work hard to ensure that pharmaceuticals maintain optimal quality all the way to the patients. At Envirotainer we believe that the best way to reach our common goal is to improve collaboration and mutual understanding across the logistics chain, we call it our eco-system thinking. Here, we share articles with our network that we think could benefit us all.

Increasing peak season challenges for pharma cold chain

The pharmaceutical industry has for many years been a prioritized customer for the air freight sector, but the increasing volumes of e-commerce have changed the game, especially at peak season. Now, pharmaceutical companies face the risk of having their products left on the tarmac due to capacity constraints, while handbags and other luxury goods are shipped with higher-yield express delivery instead.

6 challenges of pharmaceutical cold chain in India

India is the world’s third largest producer of pharmaceuticals in terms of volume. Low costs of manufacturing as well as government subsidies for biosimilars development makes India attractive for export production, with many Western-Indian partnerships, and the demand in the US and Europe is expected to sustain a high growth rate over a longer period.

Get the 2019 articles collection in an e-book

Submit your contact information and download the articles.

Was this information helpful?